Welcome to our dedicated page for Nuo Therapeutics SEC filings (Ticker: AURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuo Therapeutics, Inc. filings document a commercial-stage medical-device issuer focused on Aurix, its autologous platelet-rich plasma system for chronic wound management. The company’s regulatory record includes Current Reports on Form 8-K for material events, material agreements, capital-structure disclosures, governance matters, operating and financial results, and security-structure updates.
Proxy and annual-meeting filings describe board elections, auditor ratification, advisory executive-compensation votes, shareholder proposal procedures, and voting results. These disclosures also cover compensation arrangements, board and committee actions, common-stock matters, and public-company governance tied to commercialization of the Aurix System.
Nuo Therapeutics, Inc. director and CEO/CFO David Emerson Jorden reported acquiring 13,245 shares of Common Stock in a grant or award transaction at a weighted average price of $1.0952 per share. Following this award, he directly holds 2,085,000 shares. A footnote explains the reported price is a weighted average based on multiple transactions with individual share prices ranging from $1.042 to $1.15.
Nuo Therapeutics investor Scott M. Pittman updated his ownership and financing arrangements with the company. He now beneficially owns 5,627,500 shares of common stock, or 11.6% of the class, based on 48,408,728 shares outstanding as of May 29, 2026.
Pittman participated as a lender under a Loan and Security Agreement and an Amended and Restated Loan and Security Agreement, providing a $200,000 initial loan and a $100,000 interim loan, with an additional $100,000 commitment for a potential second closing. The secured notes bear 12% annual interest through December 31, 2028, with interest and certain prepayment fees payable in warrants rather than cash.
In connection with these loans, he received multiple series of warrants with a $1.50 per share exercise price, including Initial Warrants for 30,050 shares, Interim Warrants for 17,450 shares, Second Restated Warrants for 17,500 shares, Prepayment Restated Warrants for up to 7,333 shares, and an Interest Warrant issuable for up to 59,333 shares at maturity or earlier prepayment.
Nuo Therapeutics, Inc. director and 10% owner Scott M. Pittman reported several warrant-related transactions tied to a loan agreement. He received new Prepayment Restated, Second Restated, and Interim Warrants, each exercisable at $1.50 per share of common stock.
The filing shows cancellation of previously issued Second and Prepayment Warrants in exchange for the new restated warrants on similar terms under an Amended and Restated Loan and Security Agreement dated May 29, 2026. After these moves, he directly holds Interim Warrants for 17,450 underlying shares, with additional restated and prepayment warrants vesting only if specified funding or prepayment events occur.
Nuo Therapeutics, Inc. director and 10% owner Scott M. Pittman reported amended details for derivative awards linked to a loan arrangement. On January 23, 2026, he was granted three warrant instruments, each giving the right to buy Common Stock at an exercise price of $1.50 per share and expiring on January 23, 2031.
An integrated Initial Warrant covers 30,050 underlying shares and is immediately exercisable. A Second Warrant covers 36,750 shares and will vest, if at all, on September 30, 2026 if a Second Funding occurs under a Loan and Security Agreement dated January 21, 2026. A Prepayment Warrant covers up to 7,516 shares, vesting only upon a qualifying prepayment, but no later than December 31, 2028, under the same agreement.
The amendment primarily corrects the naming and description of the integrated Initial and Second Warrants while confirming the maximum share amounts and contingent vesting terms tied to the loan agreement.
Nuo Therapeutics entered into an Amended and Restated Loan and Security Agreement providing up to $2.0 million in secured debt funding from five lenders. This includes $1,000,000 funded in January 2026, $675,000 funded on May 29, 2026, and up to $325,000 available on September 30, 2026, subject to conditions.
The notes bear 12% annual interest, payable in stock warrants rather than cash, and mature on December 31, 2028. Principal is interest-only through 2026 and then repaid quarterly in cash starting March 31, 2027. The debt is secured by liens on all company assets, including intellectual property, and must be prepaid upon certain equity financings, changes in control, or default, with prepayment fees paid in additional warrants.
In connection with the May 29 interim funding, Nuo issued multiple classes of warrants at a $1.50 exercise price, immediately exercisable for 120,125 shares, with additional tranches tied to potential second funding, prepayments, and accrued interest. Maximum Interest Warrants cover up to 303,667 shares for full utilization and repayment of the $2.0 million facility. Related-party lenders, including board member Scott Pittman and large shareholder Paul Jacobs, participated in both the loans and warrant issuances.
Nuo Therapeutics reported first quarter 2026 results showing higher sales and a smaller loss. Total revenue reached $1,302,115 for the three months ended March 31, 2026, up from $484,381 a year earlier, driven mainly by growth in Aurix product sales and new distribution fee revenue.
Net loss narrowed to $618,466 compared with $746,128 in the prior-year quarter, as gross profit increased while operating expenses also rose. As of March 31, 2026, Nuo reported cash of $263,827, total assets of $1,945,669, total liabilities of $3,329,532, and a stockholders’ deficit of $1,383,863.
Nuo Therapeutics reported sharply higher Q1 2026 revenue but remains loss‑making and financially constrained. Total revenue rose to about $1.3 million, up from $0.5 million a year earlier, driven by Aurix growth and new private‑label sales plus $77,941 of Smith+Nephew distribution fee revenue.
Gross profit increased to roughly $0.85 million, though gross margin slipped to about 65% as centrifuge devices were sold at near break‑even transfer prices. Operating expenses rose to about $1.3 million, reflecting higher compensation and commissions, and the company posted a net loss of $618,466, narrower than the prior‑year loss of $746,128.
Cash was only $263,827 at March 31, 2026 against current liabilities of about $1.4 million, and stockholders’ deficit widened to approximately $1.4 million. Management states there is “substantial doubt” about the ability to continue as a going concern and is relying on external capital, including a new secured note facility of up to $1.6 million with warrants, of which $1.0 million is funded.
Nuo Therapeutics, Inc. files its annual report describing a small but fast-growing chronic wound-care business built around its Aurix autologous platelet-rich plasma system. Product revenue rose from approximately $1.4 million in 2024 to $3.1 million in 2025, with total 2025 revenue of about $3.3 million including distribution fees.
The company remains unprofitable, recording a net loss of roughly $2.5 million in 2025 and warning of substantial doubt about its ability to continue as a going concern without additional capital. As of June 30, 2025, non-affiliate market value was about $41.1 million, and 48,289,296 shares of common stock were outstanding as of March 26, 2026.
Nuo highlights expanding Medicare reimbursement for Aurix, including 2026 national average rates of $2,108 per treatment in hospital outpatient settings and $1,064 in physician offices. A new U.S. distribution agreement with Smith+Nephew adds a private-label channel with minimum annual purchase commitments and up to $2.25 million in fees, but the company still faces single-supplier risks, intense competition, heavy regulatory oversight and the ongoing need for financing.
Nuo Therapeutics, Inc. disclosed that investor Paul Anthony Jacobs has a significant passive stake in its common stock. As of 01/23/2026, he beneficially owned 3,183,500 shares of common stock, including 43,500 shares issuable upon exercise of immediately exercisable warrants, representing 6.6% of the outstanding class.
Jacobs reports sole voting and dispositive power over all of these shares and states they are not held for the purpose of changing or influencing control of the company.
Nuo Therapeutics director and 10% owner Scott M. Pittman reported receiving several derivative awards in the form of warrants linked to common stock at an exercise price of $1.5 per share on January 23, 2026. The grants include Commitment Warrants, Origination Initial Warrants, Capital Initial Warrants, Origination Second Warrants, Capital Second Warrants, and Prepayment Warrants, each giving the right to buy Nuo Therapeutics common stock and expiring on January 23, 2031.
Certain Second Warrants will vest, if at all, on September 30, 2026 only if a Second Funding occurs under a Loan and Security Agreement dated January 21, 2026. The Prepayment Warrants will vest, if at all, upon a Prepayment event, but no later than December 31, 2028, and the disclosed amount reflects the maximum number of shares issuable upon such a Prepayment. The company’s Board and non-employee directors approved the loan arrangement and the related warrant and share issuances.